Shibuya-ku, Tokyo, Japan, Japan, May 02, 2022, 01:03 /Comserve / -- Antinuclear antibody testing market accounted for $1,080.1 million in 2022 and is predicted to grow with a CAGR of 13.0% in the projected period.
The antinuclear antibody tests are executed with the help of a blood sample. The antibodies present in the blood serum are exposed in the laboratory to cells. It is then determined if antibodies are present in blood or not and their interaction with body cells is studied.
The pandemic situation is predicted to have a positive impact on the global autoimmune antibody testing market in the estimated period. Most business sectors have been hit vastly except healthcare institutions. Increasing number of people taking antinuclear antibody tests to examine autoimmune disorders during the pandemic period is predicted to boost the market. In addition, the global antinuclear antibody market is predicted to continue its growth and is anticipated to rise at a notable rate after recovery from the COVID-19 emergency.
Get A Sample Copy Of This Report With Graphs And Charts:- https://www.sdki.jp/sample-request-107633
Increasing cases of antinuclear antibody disorders across the globe is predicted to be a major driving factor for the global market in the estimated period. Moreover, rise in the number of people covered under medical insurance due to government initiatives to create awareness about benefits of medical insurance in critical situations is expected to boost the growth of the antinuclear antibody market in the forecast years.
The cost associated with antinuclear antibody tests is very high which is predicted to be the biggest restraint for the global market in the estimated period. Due to the high cost involved in testing the immune disease, the patients cannot afford the test which is predicted to hamper the market in the estimated timeframe.
On the basis of product, the antinuclear antibody testing market is further classified into reagents & assay kits and systems and software & services. Reagents & assay kits sub-segment generated a revenue of $642.1 million in 2019 and is predicted to grow with a CAGR of 13.6% in the estimated period. Software & Services sub-segment generated a revenue of $166.7 million in 2019 and is projected to rise with a CAGR of 12.8% in the forecast period.
On the basis of technique, the antinuclear antibody testing market is further classified into ELISA, immunofluorescence assay and multiplex assay. ELISA sub-segment generated a revenue of $430.5 million in 2019 and is projected to rise with a CAGR of 13.7% in the estimated period. Immunofluorescence assay sub-segment generated a revenue of $354.1 million in 2019 and is projected to rise with a CAGR of 13.2% in the estimated period.
On the basis of application, the antinuclear antibody testing market is further classified into rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome, scleroderma and others. Rheumatoid arthritis sub-segment generated a revenue of $752.3 million in 2019 and is projected to rise with a CAGR of 13.5% in the estimated period. Systemic lupus erythematosus sub-segment generated a revenue of $161.5 million in 2019 and is projected to rise with a CAGR of 13.3% in the estimated period.
On the basis of end use, the antinuclear antibody testing market is further classified into hospitals, clinical laboratories, physician office laboratories and others. Hospital sub-segment generated a revenue of $452.3 million in 2019 and is projected to rise with a CAGR of 12.5% in the estimated period. Physician office laboratories sub-segment generated a revenue of $223.1 million in 2019 and is projected to rise with a CAGR of 14.0% in the estimated period.
Download Sample PDF Of This Report:- https://www.sdki.jp/sample-request-107633
On the basis of region, the antinuclear antibody testing market is further classified into North America, Europe, Asia-Pacific and LAMEA. North America region market generated a revenue of $392.3 million in 2019 and is predicted to rise with a CAGR of 11.9% in the projected period. Asia-Pacific region market generated a revenue of $211.0 million in 2019 and is predicted to rise with a CAGR of 15.3% in the projected period.
Some of the significant antinuclear antibody testing market players include Erba Diagnostics, Bio-Rad Laboratories, Inc., Trinity Biotech Plc., Thermo Fisher Scientific, Antibodies Incorporated, EUROIMMUN Medizinische Labordiagnostika AG, Immuno Concepts NA Ltd., Inova Diagnostics, Inc. and ZEUS Scientific, Inc. among others.
The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.
For more information, please contact:
Lauren BrownShibuya Data Count
Email: sales@sdki.jp
Tel: + 81 50 50509159
Related Links
https://www.sdki.us/